Novel Biomarker p-tau217 Predicts Dementia Risk in Women Twenty Five Years Before Symptom Onset

UC San Diego study finds p-tau217 blood levels can predict dementia in women 25 years early, opening a new window for Alzheimer's prevention and monitoring.

By: AXL Media

Published: Mar 10, 2026, 11:51 AM EDT

Source: The information in this article was sourced from University of California - San Diego

Identifying the Decades Long Horizon of Cognitive Decline

Research published in JAMA Network Open has identified a breakthrough biological marker that can forecast a woman’s risk of dementia up to a quarter-century before clinical symptoms appear. Scientists at UC San Diego discovered that elevated levels of phosphorylated tau 217, or p-tau217, in the bloodstream serve as an early warning signal for Alzheimer's related brain changes. This discovery suggests that the physiological foundations of dementia are laid far earlier than previously understood, providing a massive window for medical intervention.

The Significance of p-tau217 as a Diagnostic Tool

The protein p-tau217 is a specific form of tau that reflects the earliest pathological shifts in the brain associated with Alzheimer's disease. According to Aladdin H. Shadyab, PhD, the lead author of the study, the ability to detect this marker in a simple blood sample represents a major shift in public health. By identifying elevated levels in cognitively healthy individuals, physicians can begin monitoring brain health long before memory loss or confusion begins to disrupt the daily lives of aging patients.

Longitudinal Evidence from the Women’s Health Initiative

The findings are rooted in data from the Women’s Health Initiative Memory Study, which tracked over 2,700 participants for up to 25 years. All of the women were cognitively unimpaired at the start of the study in the late 1990s. By analyzing blood samples taken at baseline and comparing them to cognitive outcomes decades later, the researchers established a direct, dose-response relationship: as p-tau217 levels increased, the likelihood of developing mild cognitive impairment or dementia rose proportionally.